Literature DB >> 3827903

cis-Diamminedichloroplatinum(II) selectively cross-links high mobility group proteins 1 and 2 to DNA in micrococcal nuclease accessible regions of chromatin.

W M Scovell, N Muirhead, L R Kroos.   

Abstract

The reaction of cis-diamminedichloroplatinum(II) with chicken erythrocyte nuclei produces covalent cross-linking of HMG proteins 1, 2 and E to DNA, in addition to cross-links amongst LMG proteins. This is supported by and consistent with the observations that all cross-links are chemically reversed by NaCN treatment, while only the cross-links involving the HMG proteins 1,2 and E are eliminated after a limited digestion with micrococcal nuclease. Having identified the subset of proteins selectively cross-linked to DNA by the bifunctional cis-(NH3)2PtCl2, a tentative model is proposed for the interactions between DNA and HMG proteins 1 and 2 in bulk chromatin. In addition, possible modes of action for this anti-neoplastic drug are suggested in light of these findings.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3827903     DOI: 10.1016/0006-291x(87)91488-4

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  More pronounced salt dependence and higher reactivity for platination of the hairpin r(CGCGUUGUUCGCG) compared with d(CGCGTTGTTCGCG).

Authors:  Margareta Hägerlöf; Pal Papsai; Christine S Chow; Sofi K C Elmroth
Journal:  J Biol Inorg Chem       Date:  2006-09-05       Impact factor: 3.358

2.  Towards Antitumor Active trans-Platinum Compounds.

Authors:  Sheena M Aris; Nicholas P Farrell
Journal:  Eur J Inorg Chem       Date:  2009-04-01       Impact factor: 2.524

3.  High mobility group protein, HMG-1, contains insignificant glycosyl modification.

Authors:  Y B Chao; W M Scovell; S B Yan
Journal:  Protein Sci       Date:  1994-12       Impact factor: 6.725

Review 4.  Inhibition of transcription by platinum antitumor compounds.

Authors:  Ryan C Todd; Stephen J Lippard
Journal:  Metallomics       Date:  2009       Impact factor: 4.526

5.  In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent.

Authors:  Ulrike Olszewski; Florian Ach; Ernst Ulsperger; Gerhard Baumgartner; Robert Zeillinger; Patrick Bednarski; Gerhard Hamilton
Journal:  Met Based Drugs       Date:  2009-06-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.